According to FDA statement, Becton Dickinson (BDX) is “recalling one lot of ChloraPrep Clear 1 mL applicators due to fungal contamination under ...

Barclays raised the firm’s price target on Becton Dickinson (BDX) to $279 from $278 and keeps an Overweight rating on the shares. The firm says ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

StockNews.com upgraded shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) from a hold rating to a buy rating in a research note released on Wednesday morning. Separately ...

FRANKLIN LAKES, N.J. (AP) — FRANKLIN LAKES, N.J. (AP) — Becton Dickinson and Co. (BDX) on Wednesday reported fiscal first-quarter earnings of $303 million. On a per-share basis, the Franklin ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

Becton, Dickinson and Company (BDX, Financials) announced a major strategic shift with plans to separate its Biosciences and Diagnostic Solutions unit, aiming to create two independent ...

Becton Dickinson shares have climbed 8% since the beginning of the year, while the S&P’s 500 index has increased 27%. In the final minutes of trading on Wednesday, shares hit $245.06, a rise of ...

Shares of Becton Dickinson & Co. BDX slid 7.28% to $227.21 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.36% to 6,083 ...

Bengaluru: Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its life sciences unit on Wednesday, as the medical device maker aims ...

Becton Dickinson's announcement of a separation of its biosciences and diagnostics solutions business overshadows mediocre performance of the core business. Shares are slightly down on the news.